Top

Journal of Cardiovascular Translational Research

Published in:

01-12-2009

Response of Novel Biomarkers to BNP Infusion in Patients with Decompensated Heart Failure: A Multimarker Paradigm

Authors: Wayne L. Miller, Karen A. Hartman, David O. Hodge, Stacy Hartman, Joachim Struck, Nils G. Morgenthaler, Andreas Bergmann, Allan S. Jaffe

Published in: Journal of Cardiovascular Translational Research | Issue 4/2009

Abstract

Multibiomarker paradigms have been proposed to diagnose, define progression, and to monitor therapy of heart failure (HF) patients. The aim of this study was to evaluate the prognostic and therapy-monitoring potential of four novel biomarkers (copeptin, midregional proatrial natriuretic peptide (MR-proANP), neopterin, and procalcitonin) which have been shown to be elevated in the plasma of patients with HF and reported to have prognostic value. In a prospective study of 40 patients hospitalized for decompensated HF and who received nesiritide infusions as part of their care, blood was drawn before, during, and postinfusion and assayed for the novel biomarkers. B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) which were previously measured and reported in this cohort were also included in the analyses. All biomarkers were elevated at baseline prior to nesiritide infusion, but copeptin, MR-proANP, and NT-proBNP demonstrated significant acute reductions in plasma levels in response to therapy. Copeptin levels were higher in posthospital nonsurvivors and by proportional hazards model were associated with an increased mortality risk (p = 0.04). Procalcitonin and neopterin added no incremental information on response to therapy or risk stratification. In contrast, copeptin and MR-proANP appear to have potential for monitoring acute responses to therapy. Only copeptin and BNP contributed to risk stratification in this cohort of advanced HF patients, but the conjoint use of BNP or NT-proBNP does not appear to impact the prognostic value of copeptin alone. These results are hypothesis generating to stimulate additional investigation.

Francis, G. S., Benedict, C., Johnstone, D. E., Kirlin, P. C., Nicklas, J., Liang, C. S., et al. (1990). Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation, 82, 1724–1729.PubMed

Lainchbury, J. G., Campbell, E., Frampton, C. M., Yandle, T. G., Nicholls, M. G., & Richards, A. M. (2003). Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. Journal of the American College of Cardiology, 42, 728–735.CrossRefPubMed

Maisel, A. S., McCord, J., Nowak, R. M., Hollander, J. E., Wu, A. H., Duc, P., et al. (2003). Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the breathing not properly multinational study. Journal of the American College of Cardiology, 41, 2010–2017.CrossRefPubMed

Januzzi, J. L., Camargo, C. A., Anwaruddin, S., Baggish, A. L., Chen, A. A., Krauser, D. G., et al. (2005). The N-Terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. American Journal of Cardiology, 95, 948–954.CrossRefPubMed

Wang, T. J., Larson, M. G., Levy, D., Benjamin, E. J., Leip, E. P., Omland, T., et al. (2004). Plasma natriuretic peptide levels and the risk of cardiovascular events and death. New England Journal of Medicine, 350, 655–663.CrossRefPubMed

Miller, W. L., Burnett, J. C., Hartman, K. A., Henle, M. P., Burritt, M. F., & Jaffe, A. S. (2005). Lower rather than higher levels of B-type natriuretic peptides (NT-pro-BNP and BNP) predict short-term mortality in end-stage heart failure patients treated with nesiritide. American Journal of Cardiology, 96, 837–841.CrossRefPubMed

Liang, F., O’Rear, J., Schellenberger, U., Tai, L., Lasecki, M., Schreiner, G. F., et al. (2007). Evidence for functional heterogeneity of circulating B-type natriuretic peptide. Journal of the American College of Cardiology, 49, 1071–1078.CrossRefPubMed

Lam, C. S. P., Burnett, J. C., Jr., Costello-Boerrigter, L., Rodeheffer, R. J., & Redfield, M. M. (2007). Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. Journal of the American College of Cardiology, 49, 1193–1202.CrossRefPubMed

Hammerer-Lercher, A., Halfinger, B., Sarg, B., Mair, J., Puschendorf, B., Griesmacher, A., et al. (2008). Analysis of circulating forms of proBNP and NT-proBNP in patients with severe heart failure. Clinical Chemistry, 54, 858–865.CrossRefPubMed

10.

Wu, A. H. B., & Smith, A. (2004). Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. European Journal of Heart Failure, 6, 355–358.CrossRefPubMed

11.

Bruins, S., Fokkema, M. R., Römer, J. W. P., DeJongste, M. J. L., van der Dijs, F. P. L., van den Ouweland, J. M. W., et al. (2004). High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clinical Chemistry, 50, 2052–2058.CrossRefPubMed

12.

O’Hanlon, R., O’Shea, P., Ledwidge, M., O’Loughlin, C., Lange, S., Conlon, C., et al. (2007). The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. Journal of Cardiac Failure, 13, 50–55.CrossRefPubMed

13.

Miller, W. L., Hartman, K. A., Burritt, M. F., Borgeson, D. D., Burnett, J. C., & Jaffe, A. S. (2005). Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure. Clinical Chemistry, 51, 569–577.CrossRefPubMed

14.

Gegenhuber, A., Struck, J., Dieplinger, B., Poelz, W., Pacher, R., Morgenthaler, N. G., et al. (2007). Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and copeptin to predict 1-year mortality in patients with acute destabilized heart failure. Journal of Cardiac Failure, 13(1), 42–49.CrossRefPubMed

15.

Gegenhuber, A., Struck, J., Poelz, W., Pacher, R., Morgenthaler, N. G., Bergmann, A., et al. (2006). Mid-regional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP. Clinical Chemistry, 52(5), 827–831.CrossRefPubMed

16.

von Haehling, S., Jankowska, E. A., Morgenthaler, N. G., Vassanelli, C., Zanolla, L., Rozentryt, P., et al. (2007). Comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. Journal of the American College of Cardiology, 50, 1973–1980.CrossRef

17.

Morgenthaler, N. G., Struck, J., Thomas, B., & Bergmann, A. (2004). Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clinical Chemistry, 50, 234–236.CrossRefPubMed

18.

Morgenthaler, N. G., Struck, J., Alonso, C., & Bergmann, A. (2006). Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clinical Chemistry, 52, 112–119.CrossRefPubMed

19.

Morgenthaler, N. G., Stuck, J., Fischer-Schulz, C., & Bergmann, A. (2002). Sensitive immunoluminometric assay for the detection of procalcitonin. Clinical Laboratory, 48, 788–790.

20.

Avanzas, P., Arroyo-Espliguero, R., Quiles, J., Roy, D., & Kaski, J. C. (2005). Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. European Heart Journal, 26, 457–463.CrossRefPubMed

21.

Levey, A. S., Coresh, J., Balk, E., Krausz, A. T., Levin, A., Steffes, M. W., et al. (2003). National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Annals of Internal Medicine, 139, 137–147.PubMed

22.

Stoiser, B., Morti, D., Hulsmann, M., Berger, R., Struck, J., Morgenthaler, N. G., et al. (2006). Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. European Journal of Clinical Investigation, 36, 771–778.CrossRefPubMed

23.

deBree, F. M., & Burbach, J. P. (1998). Structure–function relationships of the vasopressin prohormone domains. Cellular and Molecular Neurobiology, 18, 173–191.CrossRef

24.

Holwerda, D. A. (1972). A glycopeptide from the posterior lobe of the pig pituitaries. I. Isolation and characterization. European Journal of Biochemistry, 28, 334–339.CrossRefPubMed

25.

Robertson, G. L., Mahr, E. A., Athar, S., & Sinha, T. (1973). Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. Journal of Clinical Investigation, 52, 2340–2352.CrossRefPubMed

26.

Preibisz, J. J., Sealey, J. E., Laragh, J. H., Cody, R. J., & Weksler, B. B. (1983). Plasma and platelet vasopressin I essential hypertension and congestive heart failure. Hypertension, 5, 129–138.

27.

Struck, J., Morgenthaler, N. G., & Bergmann, A. (2005). Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides, 26, 2500–2504.CrossRefPubMed

28.

Udelson, J. E., Orlandi, C., Ouyang, J., Krasa, H., Zimmer, C. A., & Frivold, G. (2008). Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction. Journal of the American College of Cardiology, 52, 1540–1545.CrossRefPubMed

29.

Konstam, M. A., Gheorghiade, M., Burnett, J. C., Grinfeld, L., Maggioni, A. P., & Swedberg, K. (2007). Effects of oral tolvaptan in patients hospitalized for worsening heart failure. The EVEREST outcome trial. JAMA, 297, 1319–1331.CrossRefPubMed

30.

McDowell, G., Patterson, C., Maguire, S., Shaw, C., Nicholls, D. P., & Hall, C. (2002). Variability of NT-proANP and C-ANP. European Journal of Clinical Investigation, 32, 545–548.CrossRefPubMed

31.

Miller, W. L., Hartman, K. A., Grill, D. E., Burnett, J. C., Jr., & Jaffe, A. S. (2009). Only large reductions in natriuretic peptide concentrations (BNP, NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure. Clinical Chemistry, 55(1), 78–84.CrossRefPubMed

Title: Response of Novel Biomarkers to BNP Infusion in Patients with Decompensated Heart Failure: A Multimarker Paradigm
Authors: Wayne L. Miller
Karen A. Hartman
David O. Hodge
Stacy Hartman
Joachim Struck
Nils G. Morgenthaler
Andreas Bergmann
Allan S. Jaffe
Publication date: 01-12-2009
Publisher: Springer US
Published in: Journal of Cardiovascular Translational Research / Issue 4/2009
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-009-9121-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Response of Novel Biomarkers to BNP Infusion in Patients with Decompensated Heart Failure: A Multimarker Paradigm

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2009

The Left Ventricular Outflow in Hypertrophic Cardiomyopathy: From Structure to Function

Role of Animal Models in HCM Research

The Current and Emerging Role of Cardiovascular Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy

Mechanical and Energetic Consequences of HCM-Causing Mutations

A Good Idea: A Physician’s Perspective on Genetic Counseling for Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy: Preclinical and Early Phenotype